The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Ailsa.Holroyd@glasgow.ac.uk
Level 1, Zone 3, Office Block, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF
Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)
Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)
Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)
Holroyd, A. K. and Michie, A. M. (2018) The role of mTOR-mediated signaling in the regulation of cellular migration. Immunology Letters, 196, pp. 74-79. (doi: 10.1016/j.imlet.2018.01.015) (PMID:29408410)
Nakagawa, R. et al. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100(4), pp. 499-510. (doi: 10.3324/haematol.2014.112276) (PMID:25616575) (PMCID:PMC4380723)
Hay, J. et al. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14(23), 6006. (doi: 10.3390/cancers14236006) (PMID:36497487) (PMCID:PMC9735720)
Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)
Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)
Holroyd, A. K. and Michie, A. M. (2018) The role of mTOR-mediated signaling in the regulation of cellular migration. Immunology Letters, 196, pp. 74-79. (doi: 10.1016/j.imlet.2018.01.015) (PMID:29408410)
Nakagawa, R. et al. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100(4), pp. 499-510. (doi: 10.3324/haematol.2014.112276) (PMID:25616575) (PMCID:PMC4380723)
https://orcid.org/0000-0001-8687-5286